IF0 Stock Overview
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
InflaRx N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.42 |
| 52 Week High | US$4.83 |
| 52 Week Low | US$1.10 |
| Beta | 1.25 |
| 1 Month Change | 3.49% |
| 3 Month Change | -11.57% |
| 1 Year Change | -62.18% |
| 3 Year Change | -53.13% |
| 5 Year Change | -96.80% |
| Change since IPO | -88.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| IF0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.9% | -1.0% | -1.2% |
| 1Y | -62.2% | -15.4% | 1.2% |
Return vs Industry: IF0 underperformed the German Biotechs industry which returned -15.4% over the past year.
Return vs Market: IF0 underperformed the German Market which returned 1.2% over the past year.
Price Volatility
| IF0 volatility | |
|---|---|
| IF0 Average Weekly Movement | 15.2% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: IF0 has not had significant price volatility in the past 3 months.
Volatility Over Time: IF0's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 62 | Niels Riedemann | www.inflarx.de |
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
InflaRx N.V. Fundamentals Summary
| IF0 fundamental statistics | |
|---|---|
| Market cap | €83.02m |
| Earnings (TTM) | -€42.67m |
| Revenue (TTM) | €63.09k |
1,316x
P/S Ratio-1.9x
P/E RatioIs IF0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IF0 income statement (TTM) | |
|---|---|
| Revenue | €63.09k |
| Cost of Revenue | €532.26k |
| Gross Profit | -€469.17k |
| Other Expenses | €42.20m |
| Earnings | -€42.67m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.72 |
| Gross Margin | -743.67% |
| Net Profit Margin | -67,630.69% |
| Debt/Equity Ratio | 0% |
How did IF0 perform over the long term?
See historical performance and comparison